NASDAQ:AKUS Akouos (AKUS) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$13.29▼$13.2950-Day Range$13.29▼$13.2952-Week Range$2.32▼$13.60Volume440 shsAverage Volume344,411 shsMarket Capitalization$490.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Akouos alerts: Email Address Ad Brownstone ResearchIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. About Akouos Stock (NASDAQ:AKUS)Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.Read More Ad Brownstone ResearchIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.Just click here to register. AKUS Stock News HeadlinesMay 3, 2024 | benzinga.comNOVARTIS AG's Net WorthApril 5, 2024 | benzinga.comJoshua Makower's Net WorthSeptember 16, 2024 | Brownstone Research (Ad)Introducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.May 17, 2023 | health.usnews.comWilliam W. Backus HospitalMay 16, 2023 | finance.yahoo.comRectify Pharmaceuticals Appoints Sachiyo Minegishi as Chief Operating OfficerDecember 1, 2022 | finance.yahoo.comLilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesNovember 14, 2022 | finance.yahoo.comAkouos Reports Third Quarter 2022 Financial Results and Provides Business HighlightsOctober 19, 2022 | seekingalpha.comAkouos stock soars 87% as Lilly nabs hearing loss gene therapy developer - Seeking AlphaSeptember 16, 2024 | Brownstone Research (Ad)Introducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. This is my AI project that I first conceived of shortly after I recommended Nvidia back in 2016.October 18, 2022 | businesswire.comAKUS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akouos, Inc. Is Fair to Shareholders - Business WireOctober 18, 2022 | benzinga.comCrude Oil Drops Over 2%; Akouos Shares Spike Higher - Akouos (NASDAQ:AKUS), ADS-TEC Energy (NASDAQ:ADSE) - BenzingaOctober 18, 2022 | law360.comEli Lilly To Pay Up To $610M For Gene Therapy Biz Akouos - Law360October 18, 2022 | nasdaq.comEli Lilly to buy genetic medicine developer Akouos for $487 million - NasdaqOctober 18, 2022 | stockhouse.com2022-10-18 | NDAQ:AKUS | Press Release | Akouos Inc. - StockhouseOctober 18, 2022 | marketwatch.comEli Lilly to Buy Akouos for Up to $610 Million >LLY AKUS - MarketWatchOctober 18, 2022 | marketwatch.comAkouos Shares Soar on Takeover by Eli Lilly >AKUS - MarketWatchOctober 18, 2022 | marketwatch.comEli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss - MarketWatchOctober 18, 2022 | nasdaq.comEli Lilly To Buy Akouos For Up To $610 Mln - NasdaqSee More Headlines Receive AKUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akouos and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AKUS CUSIPN/A CIK1722271 Webwww.akouos.com Phone857-410-1818FaxN/AEmployees103Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.09% Return on Assets-36.86% Debt Debt-to-Equity RatioN/A Current Ratio17.30 Quick Ratio17.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.71Miscellaneous Outstanding Shares36,936,000Free Float35,163,000Market Cap$490.88 million OptionableNot Optionable Beta-0.55 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Emmanuel Simons M.B.A. (Age 39)Ph.D., Co- Founder, Pres, CEO & Director Comp: $790.72kDr. Michael John McKenna M.D. (Age 65)Co-Founder, Chief Medical Officer & Member of Scientific Advisory Board Comp: $539.35kMs. Jennifer Anne Wellman M.S. (Age 44)Chief Operating Officer Comp: $568.67kDr. Luk H. Vandenberghe M.D.Ph.D., Founder & Member of Scientific Advisory BoardMr. William F. Sewell Ph.D.Founder & Member of Scientific Advisory BoardMr. Richard Smith M.D.Founder & Member of Scientific Advisory BoardMs. Sachiyo Minegishi (Age 44)CFO, Treasurer, Assistant Sec. & Principal Accounting Officer Ms. Stacy PriceChief Technical OfficerDr. Aaron Tward M.D.Ph.D., Chief Scientific OfficerDr. Karoline K. ShairSr. VP, Gen. Counsel, Chief Legal Officer & Corp. Sec.More ExecutivesKey CompetitorsSinovac BiotechNASDAQ:SVAVanda PharmaceuticalsNASDAQ:VNDASpectrum PharmaceuticalsNASDAQ:SPPIGossamer BioNASDAQ:GOSSAlbireo PharmaNASDAQ:ALBOView All Competitors AKUS Stock Analysis - Frequently Asked Questions How were Akouos' earnings last quarter? Akouos, Inc. (NASDAQ:AKUS) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.04. When did Akouos IPO? Akouos (AKUS) raised $124 million in an IPO on Friday, June 26th 2020. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Akouos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akouos investors own include NVIDIA (NVDA), QUALCOMM (QCOM), RTX (RTX), CVS Health (CVS), Johnson & Johnson (JNJ) and Cisco Systems (CSCO). This page (NASDAQ:AKUS) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredIntroducing the PerceptronOn Wednesday, September 25, I’m putting on my first crypto event in two years to unveil: the Perceptron. Th...Brownstone Research | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akouos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akouos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.